Shaohua Q. Gou

Nanjing, 211189, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair.

Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair.

Journal: Inorganic chemistry

Published: April 17, 2026

Pt(II) Complex with FGFR4 Specificity as a Targeted Drug Conjugate for the Treatment of Hepatocellular Carcinoma.

Pt(II) Complex with FGFR4 Specificity as a Targeted Drug Conjugate for the Treatment of Hepatocellular Carcinoma.

Journal: Inorganic chemistry

Published: March 30, 2026

Hypoxia-activated dual donors of H2S and NO alleviate myocardial injury in coronary heart disease via synergistic mechanisms.

Hypoxia-activated dual donors of H2S and NO alleviate myocardial injury in coronary heart disease via synergistic mechanisms.

Journal: European journal of medicinal chemistry

Published: December 04, 2025

Concept of Targeted Drug Conjugate and Its Application in Reversing Drug Resistance.

Concept of Targeted Drug Conjugate and Its Application in Reversing Drug Resistance.

Journal: Journal of medicinal chemistry

Published: April 02, 2025

Hypoxia Activated Nitric Oxide Donor Compounds for the Prevention and Treatment of Myocardial Hypoxia-Induced Injury.

Hypoxia Activated Nitric Oxide Donor Compounds for the Prevention and Treatment of Myocardial Hypoxia-Induced Injury.

Journal: Journal of medicinal chemistry

Published: December 18, 2024

Proteolysis targeting chimera, molecular glue degrader and hydrophobic tag tethering degrader for targeted protein degradation: Mechanisms, strategies and application.

Proteolysis targeting chimera, molecular glue degrader and hydrophobic tag tethering degrader for targeted protein degradation: Mechanisms, strategies and application.

Journal: Bioorganic chemistry

Published: December 03, 2024

A Lysosome-Targeting hNEU1 Inhibitor Treats Myocardial Infarction: A Potential Therapeutic Breakthrough.

A Lysosome-Targeting hNEU1 Inhibitor Treats Myocardial Infarction: A Potential Therapeutic Breakthrough.

Journal: Journal of medicinal chemistry

Published: September 10, 2024

Discovery of the synergy between sulindac and NO expands the application of NSAIDs in cardiac complications.

Discovery of the synergy between sulindac and NO expands the application of NSAIDs in cardiac complications.

Journal: Bioorganic & medicinal chemistry

Published: August 20, 2024

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway.

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway.

Journal: Bioorganic & medicinal chemistry letters

Published: July 13, 2024

Molecular engineering of metal-based photosensitizers with narrow band gap for efficient photodynamic therapy.

Molecular engineering of metal-based photosensitizers with narrow band gap for efficient photodynamic therapy.

Journal: Chemical communications (Cambridge, England)

Published: July 01, 2024

An Approach to Apply BDNF Targeting Fe3O4-Based Nanoparticles as Multifunctional Anti-Alzheimer Agents.

An Approach to Apply BDNF Targeting Fe3O4-Based Nanoparticles as Multifunctional Anti-Alzheimer Agents.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: June 02, 2024

Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.

Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.

Journal: European journal of medicinal chemistry

Published: March 09, 2024

Showing 1-12 of 111

Last Updated: 09/26/2026